Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.
Epps C, Bax R, Croker A, Green D, Gropman A, Klein AV, Landry H, Pariser A, Rosenman M, Sakiyama M, Sato J, Sen K, Stone M, Takeuchi F, Davis JM. Epps C, et al. Among authors: sakiyama m. Ther Innov Regul Sci. 2022 Nov;56(6):964-975. doi: 10.1007/s43441-022-00409-w. Epub 2022 Apr 26. Ther Innov Regul Sci. 2022. PMID: 35471559 Free PMC article. Review.
Pediatric drug regulation: International perspectives.
Baum VC, Bax R, Heon D, Yang Z, Sakiyama M. Baum VC, et al. Among authors: sakiyama m. Paediatr Anaesth. 2019 Jun;29(6):572-582. doi: 10.1111/pan.13638. Epub 2019 Apr 14. Paediatr Anaesth. 2019. PMID: 30924233
Big Data in the Assessment of Pediatric Medication Safety.
McMahon AW, Cooper WO, Brown JS, Carleton B, Doshi-Velez F, Kohane I, Goldman JL, Hoffman MA, Kamaleswaran R, Sakiyama M, Sekine S, Sturkenboom MCJM, Turner MA, Califf RM. McMahon AW, et al. Among authors: sakiyama m. Pediatrics. 2020 Feb;145(2):e20190562. doi: 10.1542/peds.2019-0562. Epub 2020 Jan 14. Pediatrics. 2020. PMID: 31937606
Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kojima R, Kami M, Kim SW, Murashige N, Kishi Y, Hori A, Imataki O, Hamaki T, Sakiyama M, Masuo S, Fujisawa Y, Makimoto A, Heike Y, Tanosaki R, Takaue Y. Kojima R, et al. Among authors: sakiyama m. Bone Marrow Transplant. 2003 Aug;32(4):439-42. doi: 10.1038/sj.bmt.1704146. Bone Marrow Transplant. 2003. PMID: 12900783
Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0.
Sakiyama M, Kami M, Hori A, Imataki O, Hamaki T, Murashige N, Kobayashi K, Kishi Y, Kojima R, Kim SW, Kusumi E, Yuji K, Miyakoshi S, Mori S, Tanosaki R, Taniguchi S, Takaue Y; Tokyo SCT Consortium. Sakiyama M, et al. Bone Marrow Transplant. 2004 Nov;34(9):787-94. doi: 10.1038/sj.bmt.1704673. Bone Marrow Transplant. 2004. PMID: 15361909
A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease.
Hori A, Kanda Y, Goyama S, Onishi Y, Komeno Y, Mitani K, Kishi Y, Ogawa S, Imataki O, Chiba S, Kojima R, Hamaki T, Sakiyama M, Kami M, Makimoto A, Tanosaki R, Takaue Y, Hirai H; Japan Hematology and Oncology Clinical Study Group. Hori A, et al. Among authors: sakiyama m. Transplantation. 2005 Feb 15;79(3):372-4. doi: 10.1097/01.tp.0000151001.64189.1d. Transplantation. 2005. PMID: 15699774 Clinical Trial.
85 results